Matthew J Feinstein
Overview
Explore the profile of Matthew J Feinstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
1311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Filipp M, Ge Z, DeBerge M, Lantz C, Glinton K, Gao P, et al.
Circulation
. 2025 Mar;
PMID: 40071347
Background: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment options remain limited. The HFpEF syndrome is associated with a high comorbidity burden, including...
2.
Armstrong S, Chen D, Kumar S, Heath J, Feinstein M, Greenland J, et al.
Int J Mol Sci
. 2025 Feb;
26(3).
PMID: 39941136
Coronary artery disease (CAD) is linked to atherosclerosis plaque formation. In pro-inflammatory conditions, human Natural Killer (NK) cell frequencies in blood or plaque decrease; however, NK cells are underexplored in...
3.
Grunblatt E, Meng Z, Baldridge A, Patel N, Stanisic A, Feinstein M, et al.
Leuk Lymphoma
. 2025 Jan;
1-11.
PMID: 39772871
Cardiovascular adverse events (CVAEs) are recognized complications of chimeric antigen receptor (CAR) T-cell therapies. However, data are lacking regarding subtypes of adverse events that develop in patients with different malignancies,...
4.
Ruderman S, Nance R, Crane H, Cachay E, Kitahata M, Napravnik S, et al.
AIDS
. 2024 Dec;
39(5):579-583.
PMID: 39693493
Background: People with HIV (PWH) have benefited greatly from antiretroviral therapy, but face additional challenges from age-related comorbid conditions, particularly cardiovascular disease including venous thromboembolism (VTE). Little is known about...
5.
Rivera A, Al-Heeti O, Feinstein M, Williams J, Taiwo B, Achenbach C, et al.
BMJ Open
. 2024 Oct;
14(10):e085547.
PMID: 39353689
Objective: We assessed the association of early statin initiation with inpatient mortality among hospitalised COVID-19 patients. Design, Setting And Participants: This observational study emulated a hypothetical target trial using electronic...
6.
Crane H, Nance R, Ruderman S, Drumright L, Mixson L, Heckbert S, et al.
J Assoc Nurses AIDS Care
. 2024 Sep;
35(6):507-518.
PMID: 39241219
Smoking is a myocardial infarction (MI) risk factor among people with HIV (PWH). Questions persist regarding the role of smoking behaviors and measurements (e.g., intensity, duration) on MI risk. We...
7.
Wilkins J, Ning H, Allen N, Zheutlin A, Shah N, Feinstein M, et al.
J Am Coll Cardiol
. 2024 Sep;
84(11):961-973.
PMID: 39232632
Background: The ability of a 1-time measurement of non-high-density lipoprotein cholesterol (non-HDL-C) or low-density lipoprotein cholesterol (LDL-C) to predict the cumulative exposure to these lipids during early adulthood (age 18-40...
8.
Gao J, Giro P, Delaney J, Rasmussen-Torvik L, Taylor K, Thorp E, et al.
ESC Heart Fail
. 2024 Jul;
11(6):4427-4431.
PMID: 39034892
Aims: Intercellular adhesion molecule-1 (ICAM-1) facilitates inflammation via leucocyte recruitment and has been implicated in heart failure with preserved ejection fraction (HFpEF). Approximately 35% of African American individuals carry a...
9.
Grunblatt E, Feinstein M
Curr Heart Fail Rep
. 2024 Jun;
21(4):417-427.
PMID: 38940893
Purpose Of Review: People with HIV have an elevated risk of developing heart failure even with optimally controlled disease. In this review, we outline the various mechanisms through which HIV...
10.
Rivera A, Pierce J, Sinha A, Pawlowski A, Lloyd-Jones D, Lee Y, et al.
PLoS One
. 2024 Jun;
19(6):e0305467.
PMID: 38875273
Background: Emulation of the "target trial" (TT), a hypothetical pragmatic randomized controlled trial (RCT), using observational data can be used to mitigate issues commonly encountered in comparative effectiveness research (CER)...